Kevin S. Currie

Kevin S. Currie

Auto-generated profile, based on publicly available information

Kevin S. Currie

Gilead Sciences, 199 E. Blaine Street, Seattle, Washington 98102, United States

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PBPeter Blomgren
Peter Blomgren
JCJayaraman Chandrasekhar
Jayaraman Chandrasekhar
JPJulie A. Di Paolo
Julie A. Di Paolo
WFWanchi Fung
Wanchi Fung
GGGuoju Geng
Guoju Geng
KCKevin S. Currie
Kevin S. Currie

1 August 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KCKevin S. Currie
Kevin S. Currie
LPLeena Patel
Leena Patel
KSKassandra F. Sedillo
Kassandra F. Sedillo

1 October 2018 in Thrombosis Research
Verified
Journal Article
Closed access
ACAstrid S. Clarke
Astrid S. Clarke
EREmma Rousseau
Emma Rousseau
KWKelly Wang
Kelly Wang
JKJi-Yun Kim
Ji-Yun Kim
BMBernard Patrick Murray
Bernard Patrick Murray
JPJulie A. Di Paolo
Julie A. Di Paolo

1 February 2007 in ASSAY and Drug Development Technologies
Verified
Journal Article
Closed access
SJShan Jiang
Shan Jiang
JDJulie DiPaolo
Julie DiPaolo
KCKevin Currie
Kevin Currie
SAScott Alderucci
Scott Alderucci
ARArun Ramamurthy
Arun Ramamurthy
JWJ. Andrew Whitney
J. Andrew Whitney
The importance of protein kinases as a major class of drug targets across multiple diseases has generated a critical need for technologies that enable the identification of potent and selective kinase inhibitors. Bruton's tyrosine kinase (Btk) is a compelling drug target in multiple therapeutic areas, including systemic lupus erythematosus, asthma, rheumatoid arthritis, and B cell malignancies. We have combined potent, selective kinase inhibition through chemical genetics with gene expression profiling to identify a “fingerprint” of transcriptional changes associated with selective Btk kinase inhibition. The Btk transcriptional fingerprint shows remarkable relevance for Btk's biological roles and was used for functional selectivity profiling of two kinase inhibitor compounds. The fingerprint was able to rank the compounds by relative selectivity for Btk, and revealed broader off-target effects than observed in a broad panel of biochemical kinase cross screens. In addition to being useful for functional selectivity profiling, the fingerprint genes are themselves potential preclinical and clinical biomarkers for developing Btk-directed therapies.

1 December 2010 in Science-Business eXchange
Verified
Journal Article
Open access
PDF file
DPDi Paolo
Di Paolo
ACAl Nat Chem
Al Nat Chem
KCKevin S Currie
Kevin S Currie
A study in mice identified CGI1746 as a BTK inhibitor that could help treat RA.